Genes
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
85,013 comparisons from ClinicalTrials.gov. Counted 2026-11-10.
Most participants first33,758 with no events in either group come last541 to 560 of 85,013
| Comparison | With the outcome | Risk difference, 95% interval | Participants | Trial |
|---|---|---|---|---|
| No PN Use (Project B) vs PN Use (Project B): Need for Surgical Procedures (Project B) | 69 of 8,146 147 of 8,146 | -1.0 points -1.3 to -0.6 | 16,292 | NCT03767634 Outcomes Following Early Parenteral Nutrition Use in Preterm Neonates |
| No PN Use (Project B) vs PN Use (Project B): Late Onset Sepsis (Project B) | 59 of 8,146 179 of 8,146 | -1.5 points -1.9 to -1.1 | 16,292 | NCT03767634 Outcomes Following Early Parenteral Nutrition Use in Preterm Neonates |
| No PN Use (Project B) vs PN Use (Project B): Retinopathy of Prematurity (Project B) | 272 of 8,146 297 of 8,146 | -0.3 points -0.9 to 0.3 | 16,292 | NCT03767634 Outcomes Following Early Parenteral Nutrition Use in Preterm Neonates |
| No PN Use (Project B) vs PN Use (Project B): Seizures (Project B) | 81 of 8,146 114 of 8,146 | -0.4 points -0.7 to -0.1 | 16,292 | NCT03767634 Outcomes Following Early Parenteral Nutrition Use in Preterm Neonates |
| No PN Use (Project B) vs PN Use (Project B): Brain Injury on Imaging (Project B) | 48 of 8,146 73 of 8,146 | -0.3 points -0.6 to -0.0 | 16,292 | NCT03767634 Outcomes Following Early Parenteral Nutrition Use in Preterm Neonates |
| No PN Use (Project B) vs PN Use (Project B): Bronchopulmonary Dysplasia (Project B) | 302 of 8,146 619 of 8,146 | -3.9 points -4.6 to -3.2 | 16,292 | NCT03767634 Outcomes Following Early Parenteral Nutrition Use in Preterm Neonates |
| No PN Use (Project B) vs PN Use (Project B): Survival to Discharge Home (Project B) | 7,987 of 8,146 8,057 of 8,146 | -0.9 points -1.2 to -0.5 | 16,292 | NCT03767634 Outcomes Following Early Parenteral Nutrition Use in Preterm Neonates |
| High Touch vs Usual Care: Number of Staff Who Received SARS-CoV-2 Vaccine | 4,098 of 7,555 4,643 of 8,716 | 1.0 points -0.6 to 2.5 | 16,271 | NCT04732819 Improving COVID-19 Vaccine Uptake in Nursing Homes |
| ARCT-154 vs Placebo: Number of Participants With a First Occurrence of COVID-19 | 223 of 8,056 496 of 8,044 | -3.4 points -4.0 to -2.8 | 16,100 | NCT05012943 The ARCT-154 Self-Amplifying RNA Vaccine Efficacy Study (ARCT-154-01) |
| Experimental Treatment Strategy vs Reference Treatment Strategy: Number of Participants With a Composite of All-cause Mortality or Non-fatal New Q-wave Myocardial Infarction (MI) | 304 of 7,980 349 of 7,988 | -0.6 points -1.2 to 0.1 | 15,968 | NCT01813435 GLOBAL LEADERS: A Clinical Study Comparing Two Forms of Anti-platelet Therapy After Stent Implantation |
| Experimental Treatment Strategy vs Reference Treatment Strategy: Number of Participants With All-cause Mortality | 224 of 7,980 253 of 7,988 | -0.4 points -0.9 to 0.2 | 15,968 | NCT01813435 GLOBAL LEADERS: A Clinical Study Comparing Two Forms of Anti-platelet Therapy After Stent Implantation |
| Experimental Treatment Strategy vs Reference Treatment Strategy: Number of Participants With Myocardial Infarction | 248 of 7,980 250 of 7,988 | -0.0 points -0.6 to 0.5 | 15,968 | NCT01813435 GLOBAL LEADERS: A Clinical Study Comparing Two Forms of Anti-platelet Therapy After Stent Implantation |
| Experimental Treatment Strategy vs Reference Treatment Strategy: Number of Participants With a Myocardial Revascularisation | 739 of 7,980 793 of 7,988 | -0.7 points -1.6 to 0.2 | 15,968 | NCT01813435 GLOBAL LEADERS: A Clinical Study Comparing Two Forms of Anti-platelet Therapy After Stent Implantation |
| Experimental Treatment Strategy vs Reference Treatment Strategy: Number of Participants With New Q-wave Myocardial Infarction | 83 of 7,980 103 of 7,988 | -0.2 points -0.6 to 0.1 | 15,968 | NCT01813435 GLOBAL LEADERS: A Clinical Study Comparing Two Forms of Anti-platelet Therapy After Stent Implantation |
| Experimental Treatment Strategy vs Reference Treatment Strategy: Number of Participants With a Bleeding Academic Research Consortium (BARC) 3 or 5 Bleeding | 163 of 7,980 169 of 7,988 | -0.1 points -0.5 to 0.4 | 15,968 | NCT01813435 GLOBAL LEADERS: A Clinical Study Comparing Two Forms of Anti-platelet Therapy After Stent Implantation |
| Experimental Treatment Strategy vs Reference Treatment Strategy: Number of Participants With a Definite Stent Thrombosis | 64 of 7,980 64 of 7,988 | 0.0 points -0.3 to 0.3 | 15,968 | NCT01813435 GLOBAL LEADERS: A Clinical Study Comparing Two Forms of Anti-platelet Therapy After Stent Implantation |
| Experimental Treatment Strategy vs Reference Treatment Strategy: deaths from any cause | 224 of 7,980 253 of 7,988 | -0.4 points -0.9 to 0.2 | 15,968 | NCT01813435 GLOBAL LEADERS: A Clinical Study Comparing Two Forms of Anti-platelet Therapy After Stent Implantation |
| Experimental Treatment Strategy vs Reference Treatment Strategy: Number of Participants With a Composite of All-cause Mortality, Stroke, or New Q-wave Myocardial Infarction | 362 of 7,980 416 of 7,988 | -0.7 points -1.3 to -0.0 | 15,968 | NCT01813435 GLOBAL LEADERS: A Clinical Study Comparing Two Forms of Anti-platelet Therapy After Stent Implantation |
| Experimental Treatment Strategy vs Reference Treatment Strategy: Number of Participants With a Stroke | 80 of 7,980 82 of 7,988 | -0.0 points -0.3 to 0.3 | 15,968 | NCT01813435 GLOBAL LEADERS: A Clinical Study Comparing Two Forms of Anti-platelet Therapy After Stent Implantation |
| Experimental Treatment Strategy vs Reference Treatment Strategy: serious adverse events | 1,459 of 7,980 1,543 of 7,988 | -1.0 points -2.2 to 0.2 | 15,968 | NCT01813435 GLOBAL LEADERS: A Clinical Study Comparing Two Forms of Anti-platelet Therapy After Stent Implantation |
Response
The first 2 of this page's 20 results. GET /api/comparisons/v1?page=28
{
"data": {
"total": 85013,
"results": [
{
"id": "NCT03767634-1aa571bd",
"title": "No PN Use (Project B) vs PN Use (Project B): Need for Surgical Procedures (Project B)",
"summary": "69 of 8146 against 147 of 8146; risk difference -1.0 points, 95% interval -1.3 to -0.6; NCT03767634, Outcomes Following Early Parenteral Nutrition Use in Preterm Neonates",
"record": "/library/comparisons/NCT03767634-1aa571bd",
"nct_id": "NCT03767634",
"kind": "outcome",
"participants": 16292,
"risk_difference": {
"value": -0.009575251657255094,
"lower": -0.01316839213988061,
"upper": -0.006092039863011531
},
"group_1": "69 of 8,146",
"group_2": "147 of 8,146",
"difference": "-1.0 points",
"interval": "-1.3 to -0.6",
"trial_title": "Outcomes Following Early Parenteral Nutrition Use in Preterm Neonates"
},
{
"id": "NCT03767634-435f8cad",
"title": "No PN Use (Project B) vs PN Use (Project B): Late Onset Sepsis (Project B)",
"summary": "59 of 8146 against 179 of 8146; risk difference -1.5 points, 95% interval -1.9 to -1.1; NCT03767634, Outcomes Following Early Parenteral Nutrition Use in Preterm Neonates",
"record": "/library/comparisons/NCT03767634-435f8cad",
"nct_id": "NCT03767634",
"kind": "outcome",
"participants": 16292,
"risk_difference": {
"value": -0.014731156395777066,
"lower": -0.018513279436599004,
"upper": -0.011104497567864236
},
"group_1": "59 of 8,146",
"group_2": "179 of 8,146",
"difference": "-1.5 points",
"interval": "-1.9 to -1.1",
"trial_title": "Outcomes Following Early Parenteral Nutrition Use in Preterm Neonates"
}
],
"no_events": 33758,
"columns": [
{
"key": "title",
"label": "Comparison"
},
{
"key": "group_1",
"label": "With the outcome",
"under": "group_2"
},
{
"key": "difference",
"label": "Risk difference, 95% interval",
"under": "interval"
},
{
"key": "participants",
"label": "Participants"
},
{
"key": "nct_id",
"label": "Trial",
"under": "trial_title"
}
],
"order": "Most participants first",
"kinds": {
"all": 85013,
"outcome": 33568,
"serious-adverse-events": 31897,
"deaths": 19548
}
},
"release": "trial-comparisons-2026-03-23-0.1.0",
"terms": [
{
"source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
"license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "Freely available. Acknowledgement requested"
},
{
"source": "ClinicalTrials.gov",
"license": "none stated",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "None stated"
}
],
"next": "/api/comparisons/v1?page=29",
"request_id": "-aTKN9cxiPXwnwBe"
}ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
ClinicalTrials.gov
Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.
Patent publications
Paste a sequence and see the patents that disclose it.
For invited accounts.
Opens sequences.conductscience.org
For software
Every answer on this page is also JSON, under /api/comparisons/v1. No key.
GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome
Ask an assistant